Abstract:Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of malignant plasma cells. The pathogenesis of MM involves the interaction between MM cells and the bone marrow microenvironment through soluble cytokines and cell adhesion molecules, which activate various signaling pathways such as PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways. Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma cells, making them attractive targets for therapeutic intervention. Currently, approved drugs targeting these signaling pathways in MM are limited, with many inhibitors and inducers still in preclinical or clinical research stages. Therapeutic options for MM include non-targeted drugs like alkylating agents, corticosteroids, immunomodulatory drugs, proteasome inhibitors, and histone deacetylase inhibitors. Additionally, targeted drugs such as monoclonal antibodies, chimeric antigen receptor T cells, bispecific T-cell engagers, and bispecific antibodies are being used in MM treatment. Despite significant advancements in MM treatment, the disease remains incurable, emphasizing the need for the development of novel or combined targeted therapies based on emerging theoretical knowledge, technologies, and platforms. In this review, we highlight the key role of signaling pathways in the malignant progression and treatment of MM, exploring advances in targeted therapy and potential treatments to offer further insights for improving MM management and outcomes.

Targeting the signal pathways as treatments for multiple myeloma

Multiple myeloma: signaling pathways and targeted therapy

Targeting Signaling Pathways in Multiple Myeloma: Pathogenesis and Implication for Treatments.

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy

Rna Interference For Multiple Myeloma Therapy: Targeting Signal Transduction Pathways

Targeted immunotherapy: harnessing the immune system to battle multiple myeloma

Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside

Multiple myeloma, immunotherapy and minimal residual disease

Advances in Research on Potential Inhibitors of Multiple Myeloma

Molecular Biological Characterization and Targeted Therapy Strategy of Multiple Myeloma

T Cell-Based Targeted Immunotherapies For Patients With Multiple Myeloma

Multiple Myeloma Therapy: Emerging Trends and Challenges

Targeted therapy for multiple myeloma: an overview on CD138-based strategies

Molecular Basis and Potential Molecular Mechanisms of Action in Natural Products as Therapeutic Agents Towards Multiple Myeloma

Recent advance of small-molecule drugs for clinical treatment of multiple myeloma

Myeloma stem/progenitor cells as new targets for therapy of multiple myeloma--review]

Roles of miRNA dysregulation in the pathogenesis of multiple myeloma

Targeting the Oncogenic Transcription Factor C-Maf for the Treatment of Multiple Myeloma.

[Research progress in targeting GPRC5D for the treatment of multiple myeloma]